China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership to enhance their collaboration in new drug R&D technical services, drug administration and regulation consultation, brand linkage communication, and more. This partnership builds on their existing collaboration, which has already yielded significant results in the field of drug development.
Existing Collaboration and Achievements
The two companies have previously worked together on one-stop services spanning the development of process/prescription of raw materials and preparations of drugs in the field of small nucleic acids, pharmacokinetics, and toxicology research. They have also collaborated on the development and application of new varieties of biological drugs, as well as research and clinical services. In October 2022, Asymchem’s CDMO unit facilitated the clinical trial approval for MY-586, a nasal spray COVID-19 neutralizing antibody developed by AusperBio’s joint venture.
Scope of the Partnership
The strategic partnership will expand their collaboration to include broader areas of new drug R&D technical services, drug administration and regulation consultation, and brand linkage communication. This comprehensive approach aims to enhance the efficiency and effectiveness of drug development processes, providing innovative solutions to the pharmaceutical industry.
Significance of the Alliance
This alliance underscores the commitment of both AusperBio and Asymchem to advancing the development of innovative drugs and improving the overall drug development ecosystem. By combining their expertise and resources, the companies aim to accelerate the delivery of new treatments to patients and strengthen their positions in the global pharmaceutical market.-Fineline Info & Tech
